Burden of vaso‐occlusive crisis, its management and impact on quality of life of Indian sickle cell disease patients
British Journal of Haematology · 2025-01 · 206 (1) · 296-309
DOI: 10.1111/bjh.19829 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift British Journal of Haematology, online erschienen am 28.10.2024. Verfasst von Tulika Seth und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, All-India Institute of Medical Sciences, New Delhi, Delhi, India. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Quality of Life. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novartis Healthcare Private Limited.
Abstract (Originalsprache)
Sickle cell disease (SCD) with vaso‐occlusive pain crisis (VOC) significantly impacts patient well‐being and often results in extensive healthcare resource utilization. This study assessed the VOC burden, its management and its impact on patients' quality of life (QoL). A cross‐sectional observational study was conducted between November 2021 and June 2022, including 1000 SCD patients from high‐prevalence states in India. Data on demographics, clinical characteristics, VOC severity, management and QoL were collected. The study revealed that 33.5% of patients reported at least one VOC episode during the study period. In the year prior to their enrolment, 836 (83.60%) patients reported at least one VOC episode, with an equal proportion of 407/487 (83.6%) adults and 429/513 (83.6%) paediatric patients, reducing their QoL across all domains compared to patients without VOC. Of these, 469/1000 patients (46.9%) experienced ≥3 VOC episodes. Additionally, 764/1000 (76.40%) patients managed their VOCs at healthcare facilities, with 501/1000 (50.1%) requiring inpatient admissions. Further, 71.80% of patients received Hydroxyurea (HU) therapy. The study depicts the severity of the Arab–Indian haplotype in Indian SCD patients visiting healthcare settings based on high VOC burden. This highlights the urgent need for better management strategies and resource allocation for these patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, All-India Institute of Medical Sciences, New Delhi, Delhi, India.
- Department of Oncology Medical Affairs, Novartis Healthcare Private Limited, Mumbai, Maharashtra, India.
- Thalassemia and Sickle Cell Society, Hyderabad, Telangana, India.
- Haemato Oncology Care Centre, Vadodara, Gujarat, India.
- ASHWINI Gudalur Adivasi Hospital, Gudalur, Tamil Nadu, India.
- Srirama Chandra Bhanj Medical College & Hospital, Cuttack, Odisha, India.
ORCID-Profile: Suman Jain, Ravindra Kumar, Shomik Ray, Dipty Jain
Förderung
- Novartis Healthcare Private Limited
Zitieren
APA
Seth, T., Udupi, S., Jain, S., Bhatwadekar, S., Menon, N., Jena, R. K., Kumar, R., Ray, S., Parmar, B., Goel, A. K., Vasava, A., Dutta, A., Samal, P., Ballikar, R., Bhat, D., Dolai, T. K., Bhattacharyya, J., Shetty, D., Mistry, M., & Jain, D. (2025). Burden of vaso‐occlusive crisis, its management and impact on quality of life of Indian sickle cell disease patients. British Journal of Haematology, 206(1), 296-309. https://doi.org/10.1111/bjh.19829
Vancouver
Seth T, Udupi S, Jain S, Bhatwadekar S, Menon N, Jena RK, et al. Burden of vaso‐occlusive crisis, its management and impact on quality of life of Indian sickle cell disease patients. British Journal of Haematology. 2025;206(1):296-309. doi:10.1111/bjh.19829
BibTeX
@article{Seth2025,
author = {Seth, Tulika and Udupi, Shashank and Jain, Suman and Bhatwadekar, Seema and Menon, Nandakumar and Jena, Rabindra Kumar and Kumar, Ravindra and Ray, Shomik and Parmar, Bharat and Goel, Anil Kumar and Vasava, Ashvin and Dutta, Anupam and Samal, Priyanka and Ballikar, Riya and Bhat, Deepa and Dolai, Tuphan Kanti and Bhattacharyya, Jina and Shetty, Disha and Mistry, Manish and Jain, Dipty},
title = {Burden of vaso‐occlusive crisis, its management and impact on quality of life of Indian sickle cell disease patients},
journal = {British Journal of Haematology},
year = {2025},
volume = {206},
number = {1},
pages = {296--309},
doi = {10.1111/bjh.19829}
}
EUVIMED